Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Stock Competitors & Peer Comparison
See IOVA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for IOVA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IOVA | $7.82 | +10.08% | 3.1B | -7.40 | -$0.95 | N/A |
| VRTX | $547.59 | +6.21% | 134.1B | 27.76 | $19.03 | N/A |
| REGN | $841.06 | +4.36% | 83.5B | 17.76 | $45.63 | +0.45% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,020.84 | +3.34% | 61.8B | 89.62 | $11.08 | N/A |
| RVMDW | $12.24 | +1.66% | 48.8B | -1.72 | -$7.21 | N/A |
| RVMD | $213.44 | +0.68% | 45.9B | -24.49 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $376.36 | +3.82% | 39.4B | 64.99 | $5.68 | N/A |
| ALNY | $242.38 | +7.92% | 30.6B | 41.19 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
IOVA vs VRTX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, VRTX has a market cap of 134.1B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while VRTX trades at $547.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas VRTX's P/E ratio is 27.76. In terms of profitability, IOVA's ROE is -0.41%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, IOVA is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
IOVA vs REGN Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, REGN has a market cap of 83.5B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while REGN trades at $841.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas REGN's P/E ratio is 17.76. In terms of profitability, IOVA's ROE is -0.41%, compared to REGN's ROE of +0.14%. Regarding short-term risk, IOVA is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
IOVA vs VRNA Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas VRNA's P/E ratio is -102.80. In terms of profitability, IOVA's ROE is -0.41%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, IOVA is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
IOVA vs ARGX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ARGX has a market cap of 61.8B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ARGX trades at $1,020.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ARGX's P/E ratio is 89.62. In terms of profitability, IOVA's ROE is -0.41%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, IOVA is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ARGX's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
IOVA vs RVMDW Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, RVMDW has a market cap of 48.8B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while RVMDW trades at $12.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas RVMDW's P/E ratio is -1.72. In terms of profitability, IOVA's ROE is -0.41%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, IOVA is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
IOVA vs RVMD Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, RVMD has a market cap of 45.9B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while RVMD trades at $213.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas RVMD's P/E ratio is -24.49. In terms of profitability, IOVA's ROE is -0.41%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, IOVA is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
IOVA vs SGEN Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IOVA's ROE is -0.41%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IOVA is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
IOVA vs ONC Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ONC has a market cap of 39.4B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ONC trades at $376.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ONC's P/E ratio is 64.99. In terms of profitability, IOVA's ROE is -0.41%, compared to ONC's ROE of +0.14%. Regarding short-term risk, IOVA is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
IOVA vs ALNY Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ALNY has a market cap of 30.6B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ALNY trades at $242.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ALNY's P/E ratio is 41.19. In terms of profitability, IOVA's ROE is -0.41%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, IOVA is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ALNY's competition here
Insmed Incorporated (NASDAQ: INSM)
IOVA vs INSM Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, INSM has a market cap of 27.8B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while INSM trades at $128.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas INSM's P/E ratio is -28.11. In terms of profitability, IOVA's ROE is -0.41%, compared to INSM's ROE of -1.11%. Regarding short-term risk, IOVA is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
IOVA vs ROIV Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ROIV has a market cap of 27B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ROIV trades at $36.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ROIV's P/E ratio is -35.55. In terms of profitability, IOVA's ROE is -0.41%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, IOVA is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
IOVA vs INCY Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, INCY has a market cap of 25B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while INCY trades at $128.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas INCY's P/E ratio is 16.60. In terms of profitability, IOVA's ROE is -0.41%, compared to INCY's ROE of +0.30%. Regarding short-term risk, IOVA is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check INCY's competition here
Moderna, Inc. (NASDAQ: MRNA)
IOVA vs MRNA Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, MRNA has a market cap of 25B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while MRNA trades at $149.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas MRNA's P/E ratio is -7.73. In terms of profitability, IOVA's ROE is -0.41%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, IOVA is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for IOVA.Check MRNA's competition here
BioNTech SE (NASDAQ: BNTX)
IOVA vs BNTX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, BNTX has a market cap of 23B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while BNTX trades at $110.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas BNTX's P/E ratio is -16.58. In terms of profitability, IOVA's ROE is -0.41%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, IOVA is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
IOVA vs UTHR Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while UTHR trades at $526.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas UTHR's P/E ratio is 18.54. In terms of profitability, IOVA's ROE is -0.41%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, IOVA is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
IOVA vs GMAB Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, GMAB has a market cap of 20.2B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while GMAB trades at $33.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas GMAB's P/E ratio is 24.84. In terms of profitability, IOVA's ROE is -0.41%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, IOVA is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
IOVA vs BGNE Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IOVA's ROE is -0.41%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, IOVA is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
IOVA vs DNA-WT Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IOVA's ROE is -0.41%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, IOVA is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
IOVA vs JAZZ Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while JAZZ trades at $253.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas JAZZ's P/E ratio is 9.44. In terms of profitability, IOVA's ROE is -0.41%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, IOVA is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
IOVA vs BBIO Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, BBIO has a market cap of 15.6B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while BBIO trades at $83.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas BBIO's P/E ratio is -21.36. In terms of profitability, IOVA's ROE is -0.41%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, IOVA is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check BBIO's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
IOVA vs NBIX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, NBIX has a market cap of 15.5B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while NBIX trades at $155.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas NBIX's P/E ratio is 22.29. In terms of profitability, IOVA's ROE is -0.41%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, IOVA is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
IOVA vs ASND Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ASND has a market cap of 15.5B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ASND trades at $257.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ASND's P/E ratio is -102.83. In terms of profitability, IOVA's ROE is -0.41%, compared to ASND's ROE of +1.90%. Regarding short-term risk, IOVA is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
IOVA vs EXEL Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, EXEL has a market cap of 13.4B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while EXEL trades at $54.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas EXEL's P/E ratio is 15.18. In terms of profitability, IOVA's ROE is -0.41%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, IOVA is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check EXEL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
IOVA vs BMRN Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, BMRN has a market cap of 12.9B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while BMRN trades at $68.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas BMRN's P/E ratio is 32.04. In terms of profitability, IOVA's ROE is -0.41%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, IOVA is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check BMRN's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
IOVA vs KRTX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IOVA's ROE is -0.41%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IOVA is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check KRTX's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
IOVA vs HALO Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, HALO has a market cap of 12.4B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while HALO trades at $107.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas HALO's P/E ratio is 19.57. In terms of profitability, IOVA's ROE is -0.41%, compared to HALO's ROE of +1.81%. Regarding short-term risk, IOVA is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check HALO's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
IOVA vs ARWR Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ARWR has a market cap of 12.4B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ARWR trades at $88.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ARWR's P/E ratio is -39.07. In terms of profitability, IOVA's ROE is -0.41%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, IOVA is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
IOVA vs MDGL Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, MDGL has a market cap of 12.1B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while MDGL trades at $534.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas MDGL's P/E ratio is -40.97. In terms of profitability, IOVA's ROE is -0.41%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, IOVA is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
IOVA vs TECH Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while TECH trades at $72.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas TECH's P/E ratio is 37.23. In terms of profitability, IOVA's ROE is -0.41%, compared to TECH's ROE of +0.09%. Regarding short-term risk, IOVA is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
IOVA vs RNAM Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas RNAM's P/E ratio is -17.39. In terms of profitability, IOVA's ROE is -0.41%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, IOVA is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
IOVA vs AXSM Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, AXSM has a market cap of 11.1B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while AXSM trades at $219.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas AXSM's P/E ratio is -56.32. In terms of profitability, IOVA's ROE is -0.41%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, IOVA is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check AXSM's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
IOVA vs PRAX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, PRAX has a market cap of 10.3B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while PRAX trades at $382.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas PRAX's P/E ratio is -28.60. In terms of profitability, IOVA's ROE is -0.41%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, IOVA is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check PRAX's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
IOVA vs SMMT Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, SMMT has a market cap of 10.2B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while SMMT trades at $13.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas SMMT's P/E ratio is -8.01. In terms of profitability, IOVA's ROE is -0.41%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, IOVA is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check SMMT's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
IOVA vs PTGX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, PTGX has a market cap of 10.1B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while PTGX trades at $155.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas PTGX's P/E ratio is 152.76. In terms of profitability, IOVA's ROE is -0.41%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, IOVA is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check PTGX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
IOVA vs KYMR Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, KYMR has a market cap of 10B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while KYMR trades at $125.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas KYMR's P/E ratio is -37.93. In terms of profitability, IOVA's ROE is -0.41%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, IOVA is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check KYMR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
IOVA vs IONS Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, IONS has a market cap of 9.9B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while IONS trades at $60.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas IONS's P/E ratio is -34.66. In terms of profitability, IOVA's ROE is -0.41%, compared to IONS's ROE of -1.11%. Regarding short-term risk, IOVA is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check IONS's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
IOVA vs KRYS Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, KRYS has a market cap of 9.8B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while KRYS trades at $343.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas KRYS's P/E ratio is 41.71. In terms of profitability, IOVA's ROE is -0.41%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, IOVA is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
IOVA vs RXDX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IOVA's ROE is -0.41%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IOVA is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check RXDX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
IOVA vs CYTK Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, CYTK has a market cap of 9.5B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while CYTK trades at $77.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas CYTK's P/E ratio is -12.26. In terms of profitability, IOVA's ROE is -0.41%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, IOVA is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check CYTK's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
IOVA vs SYRE Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, SYRE has a market cap of 9.4B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while SYRE trades at $107.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas SYRE's P/E ratio is -55.29. In terms of profitability, IOVA's ROE is -0.41%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, IOVA is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
IOVA vs IMVT Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, IMVT has a market cap of 9.1B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while IMVT trades at $44.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas IMVT's P/E ratio is -15.71. In terms of profitability, IOVA's ROE is -0.41%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, IOVA is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check IMVT's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
IOVA vs NUVL Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas NUVL's P/E ratio is -21.79. In terms of profitability, IOVA's ROE is -0.41%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, IOVA is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
IOVA vs CRNX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while CRNX trades at $84.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas CRNX's P/E ratio is -16.81. In terms of profitability, IOVA's ROE is -0.41%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, IOVA is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check CRNX's competition here
Abivax S.A. (NASDAQ: ABVX)
IOVA vs ABVX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ABVX trades at $120.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ABVX's P/E ratio is -62.35. In terms of profitability, IOVA's ROE is -0.41%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, IOVA is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ABVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
IOVA vs IMGN Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IOVA's ROE is -0.41%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, IOVA is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check IMGN's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
IOVA vs PCVX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while PCVX trades at $62.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas PCVX's P/E ratio is -7.84. In terms of profitability, IOVA's ROE is -0.41%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, IOVA is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check PCVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
IOVA vs BPMC Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IOVA's ROE is -0.41%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, IOVA is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
IOVA vs APGE Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while APGE trades at $134.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas APGE's P/E ratio is -31.08. In terms of profitability, IOVA's ROE is -0.41%, compared to APGE's ROE of -0.30%. Regarding short-term risk, IOVA is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check APGE's competition here
Alkermes plc (NASDAQ: ALKS)
IOVA vs ALKS Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ALKS has a market cap of 8.3B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ALKS trades at $50.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ALKS's P/E ratio is 52.08. In terms of profitability, IOVA's ROE is -0.41%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, IOVA is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ALKS's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
IOVA vs CERE Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas CERE's P/E ratio is -16.47. In terms of profitability, IOVA's ROE is -0.41%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IOVA is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check CERE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
IOVA vs IBRX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, IBRX has a market cap of 8.1B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while IBRX trades at $8.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas IBRX's P/E ratio is -7.96. In terms of profitability, IOVA's ROE is -0.41%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, IOVA is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
IOVA vs RYTM Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, RYTM has a market cap of 7.9B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while RYTM trades at $116.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas RYTM's P/E ratio is -37.06. In terms of profitability, IOVA's ROE is -0.41%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, IOVA is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check RYTM's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
IOVA vs TGTX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, TGTX has a market cap of 7.7B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while TGTX trades at $51.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas TGTX's P/E ratio is 18.21. In terms of profitability, IOVA's ROE is -0.41%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, IOVA is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check TGTX's competition here
Metsera, Inc. (NASDAQ: MTSR)
IOVA vs MTSR Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas MTSR's P/E ratio is -23.58. In terms of profitability, IOVA's ROE is -0.41%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, IOVA is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
IOVA vs MRUS Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas MRUS's P/E ratio is -17.05. In terms of profitability, IOVA's ROE is -0.41%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, IOVA is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check MRUS's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
IOVA vs ORKA Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ORKA has a market cap of 6.8B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ORKA trades at $108.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ORKA's P/E ratio is -58.29. In terms of profitability, IOVA's ROE is -0.41%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, IOVA is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ORKA's competition here
Arcellx, Inc. (NASDAQ: ACLX)
IOVA vs ACLX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ACLX's P/E ratio is -28.27. In terms of profitability, IOVA's ROE is -0.41%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, IOVA is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ACLX's competition here
CG Oncology Inc. (NASDAQ: CGON)
IOVA vs CGON Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, CGON has a market cap of 6.7B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while CGON trades at $79.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas CGON's P/E ratio is -28.36. In terms of profitability, IOVA's ROE is -0.41%, compared to CGON's ROE of -0.25%. Regarding short-term risk, IOVA is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check CGON's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
IOVA vs RETA Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas RETA's P/E ratio is -66.29. In terms of profitability, IOVA's ROE is -0.41%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IOVA is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check RETA's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
IOVA vs SRRK Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while SRRK trades at $55.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas SRRK's P/E ratio is -15.86. In terms of profitability, IOVA's ROE is -0.41%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, IOVA is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check SRRK's competition here
Belite Bio, Inc (NASDAQ: BLTE)
IOVA vs BLTE Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while BLTE trades at $167.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas BLTE's P/E ratio is -87.28. In terms of profitability, IOVA's ROE is -0.41%, compared to BLTE's ROE of -0.21%. Regarding short-term risk, IOVA is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check BLTE's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
IOVA vs DNTH Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, DNTH has a market cap of 6.5B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while DNTH trades at $113.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas DNTH's P/E ratio is -27.84. In terms of profitability, IOVA's ROE is -0.41%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, IOVA is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
IOVA vs COGT Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, COGT has a market cap of 6.4B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while COGT trades at $36.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas COGT's P/E ratio is -17.73. In terms of profitability, IOVA's ROE is -0.41%, compared to COGT's ROE of -0.73%. Regarding short-term risk, IOVA is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check COGT's competition here
Erasca, Inc. (NASDAQ: ERAS)
IOVA vs ERAS Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ERAS trades at $17.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ERAS's P/E ratio is -19.46. In terms of profitability, IOVA's ROE is -0.41%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, IOVA is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ERAS's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
IOVA vs CNTA Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas CNTA's P/E ratio is -22.63. In terms of profitability, IOVA's ROE is -0.41%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, IOVA is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check CNTA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
IOVA vs MIRM Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, MIRM has a market cap of 6.2B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while MIRM trades at $104.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas MIRM's P/E ratio is -6.93. In terms of profitability, IOVA's ROE is -0.41%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, IOVA is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check MIRM's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
IOVA vs DFTX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, DFTX has a market cap of 6.1B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while DFTX trades at $44.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas DFTX's P/E ratio is N/A. In terms of profitability, IOVA's ROE is -0.41%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, IOVA is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check DFTX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
IOVA vs XENE Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while XENE trades at $62.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas XENE's P/E ratio is -13.44. In terms of profitability, IOVA's ROE is -0.41%, compared to XENE's ROE of -0.44%. Regarding short-term risk, IOVA is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check XENE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
IOVA vs PTCT Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while PTCT trades at $73.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas PTCT's P/E ratio is -31.17. In terms of profitability, IOVA's ROE is -0.41%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, IOVA is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check PTCT's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
IOVA vs TVTX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, TVTX has a market cap of 5.9B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while TVTX trades at $65.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas TVTX's P/E ratio is -142.00. In terms of profitability, IOVA's ROE is -0.41%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, IOVA is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check TVTX's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
IOVA vs CAI Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, CAI has a market cap of 5.9B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while CAI trades at $22.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas CAI's P/E ratio is 58.92. In terms of profitability, IOVA's ROE is -0.41%, compared to CAI's ROE of +0.19%. Regarding short-term risk, IOVA is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check CAI's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
IOVA vs LGND Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while LGND trades at $286.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas LGND's P/E ratio is 31.57. In terms of profitability, IOVA's ROE is -0.41%, compared to LGND's ROE of +0.20%. Regarding short-term risk, IOVA is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
IOVA vs CDTX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas CDTX's P/E ratio is -19.77. In terms of profitability, IOVA's ROE is -0.41%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, IOVA is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
IOVA vs ABCM Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IOVA's ROE is -0.41%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IOVA is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
IOVA vs ISEE Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IOVA's ROE is -0.41%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IOVA is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
IOVA vs APLS Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas APLS's P/E ratio is 38.35. In terms of profitability, IOVA's ROE is -0.41%, compared to APLS's ROE of +0.40%. Regarding short-term risk, IOVA is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check APLS's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
IOVA vs ACAD Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ACAD has a market cap of 5.2B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ACAD trades at $30.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ACAD's P/E ratio is 14.65. In terms of profitability, IOVA's ROE is -0.41%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, IOVA is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ACAD's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
IOVA vs CRSP Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while CRSP trades at $58.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas CRSP's P/E ratio is -11.13. In terms of profitability, IOVA's ROE is -0.41%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, IOVA is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check CRSP's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
IOVA vs DYN Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, DYN has a market cap of 4.9B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while DYN trades at $26.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas DYN's P/E ratio is -8.07. In terms of profitability, IOVA's ROE is -0.41%, compared to DYN's ROE of -0.64%. Regarding short-term risk, IOVA is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check DYN's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
IOVA vs TERN Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas TERN's P/E ratio is -51.41. In terms of profitability, IOVA's ROE is -0.41%, compared to TERN's ROE of -0.20%. Regarding short-term risk, IOVA is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check TERN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
IOVA vs EWTX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, EWTX has a market cap of 4.7B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while EWTX trades at $45.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas EWTX's P/E ratio is -23.84. In terms of profitability, IOVA's ROE is -0.41%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, IOVA is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check EWTX's competition here
Veradermics, Incorporated (NYSE: MANE)
IOVA vs MANE Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while MANE trades at $111.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas MANE's P/E ratio is -35.50. In terms of profitability, IOVA's ROE is -0.41%, compared to MANE's ROE of -0.29%. Regarding short-term risk, IOVA is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check MANE's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
IOVA vs PBLS Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, PBLS has a market cap of 4.6B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while PBLS trades at $40.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas PBLS's P/E ratio is -44.72. In terms of profitability, IOVA's ROE is -0.41%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, IOVA is more volatile compared to PBLS. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check PBLS's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
IOVA vs FOLD Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas FOLD's P/E ratio is -161.00. In terms of profitability, IOVA's ROE is -0.41%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, IOVA is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check FOLD's competition here
Celcuity Inc. (NASDAQ: CELC)
IOVA vs CELC Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while CELC trades at $92.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas CELC's P/E ratio is -21.68. In terms of profitability, IOVA's ROE is -0.41%, compared to CELC's ROE of -3.51%. Regarding short-term risk, IOVA is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check CELC's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
IOVA vs RLAY Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, RLAY has a market cap of 4.5B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while RLAY trades at $20.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas RLAY's P/E ratio is -13.13. In terms of profitability, IOVA's ROE is -0.41%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, IOVA is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check RLAY's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
IOVA vs AKRO Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas AKRO's P/E ratio is -14.57. In terms of profitability, IOVA's ROE is -0.41%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, IOVA is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
IOVA vs ALPN Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IOVA's ROE is -0.41%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IOVA is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ALPN's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
IOVA vs ELVN Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ELVN has a market cap of 4.3B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ELVN trades at $58.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ELVN's P/E ratio is -35.97. In terms of profitability, IOVA's ROE is -0.41%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, IOVA is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ELVN's competition here
Opthea Limited (NASDAQ: OPT)
IOVA vs OPT Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas OPT's P/E ratio is -1.52. In terms of profitability, IOVA's ROE is -0.41%, compared to OPT's ROE of +1.18%. Regarding short-term risk, IOVA is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
IOVA vs PRTC Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas PRTC's P/E ratio is -3.78. In terms of profitability, IOVA's ROE is -0.41%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, IOVA is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check PRTC's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
IOVA vs TNGX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, TNGX has a market cap of 4.1B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while TNGX trades at $25.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas TNGX's P/E ratio is -30.65. In terms of profitability, IOVA's ROE is -0.41%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, IOVA is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check TNGX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
IOVA vs MRTX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IOVA's ROE is -0.41%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IOVA is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check MRTX's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
IOVA vs LEGN Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, LEGN has a market cap of 4.1B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while LEGN trades at $22.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas LEGN's P/E ratio is -32.24. In terms of profitability, IOVA's ROE is -0.41%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, IOVA is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check LEGN's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
IOVA vs TLX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, TLX has a market cap of 4B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while TLX trades at $12.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas TLX's P/E ratio is -645.65. In terms of profitability, IOVA's ROE is -0.41%, compared to TLX's ROE of -0.02%. Regarding short-term risk, IOVA is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check TLX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
IOVA vs ADPT Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while ADPT trades at $25.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas ADPT's P/E ratio is -59.90. In terms of profitability, IOVA's ROE is -0.41%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, IOVA is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check ADPT's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
IOVA vs AMLX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, AMLX has a market cap of 3.9B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while AMLX trades at $38.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas AMLX's P/E ratio is -23.41. In terms of profitability, IOVA's ROE is -0.41%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, IOVA is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for IOVA.Check AMLX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
IOVA vs VKTX Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, VKTX has a market cap of 3.9B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while VKTX trades at $34.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas VKTX's P/E ratio is -8.06. In terms of profitability, IOVA's ROE is -0.41%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, IOVA is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
IOVA vs DNLI Comparison August 2026
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IOVA stands at 3.1B. In comparison, DNLI has a market cap of 3.9B. Regarding current trading prices, IOVA is priced at $7.82 on the NASDAQ, while DNLI trades at $25.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IOVA currently has a P/E ratio of -7.40, whereas DNLI's P/E ratio is -8.44. In terms of profitability, IOVA's ROE is -0.41%, compared to DNLI's ROE of -0.55%. Regarding short-term risk, IOVA is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for IOVA.Check DNLI's competition here